Silence Therapeutics appoints chief medical adviser

pharmafile | September 19, 2012 | Appointment | Business Services, Research and Development, Sales and Marketing Michael Khan, Silence Therapeutics 

Silence Therapeutics has announced the appointment of Michael Khan to its board of directors as chief medical adviser.

Dr Khan is an associate professor of Medicine at the University of Warwick and a Consultant Physician at University Hospitals. He trained in medicine at Guy’s and King’s in London and completed specialist training at University College London, Middlesex and Whittington Hospitals.

Khan is a previous head of Molecular Medicine at Warwick University and has held numerous research grants in cell and molecular biology. He and co-workers have made important contributions to further understanding of cancer cell biology and diabetes and are working on identifying novel tissue-based biomarkers for colorectal cancer and the development of novel diagnostic tools.

He is a fellow of the Royal College of Physicians of London and a member of the Association of Physicians, HEART-UK and Diabetes UK and has acted as an expert advisor to numerous National and International Organisations in both the public and private sectors.

Related Content

partnership

AstraZeneca to leverage Silence Therapeutics’ siRNA expertise in $480mn deal

Silence Therapeutics has revealed it has struck a new collaboration with AstraZeneca which will trigger …

AstraZeneca extends siRNA collaboration

AstraZeneca has agreed a one-year extension on its siRNA development collaboration with London-based Silence Therapeutics. …

Latest content